Go Ad-Free
    My Alerts
    VICTORIS
    Budget Express 2026

    co-presented by

    • LIC
    • JIO BlackRock

    ASSOCIATE SPONSORS

    • Sunteck
    • SBI
    • Emirates
    • Dezerv
    Loans
    Loans
    HomeNewsGlenmark pharmaceuticals sa

    Glenmark Pharmaceuticals Sa

    Jump to

    • Glenmark's novel antibody GBR 1302 to enter clinical trials

      GBR 1302, a bi-specific monoclonal antibody, is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.

    • Glenmark Pharma a top pick in pharma space: Macquarie

      In an exclusive interview with CNBC TV-18's Udayan Mukherjee and Mitali Mukherjee, Abhishek Singhal of Macquarie, said that Glenmark would be his top pick in the Indian pharma space since sentiment is positive for the pharma firm after its pact with pharma major Sanofi.

    • Glenmark Pharma in licensing deal with Sanofi

      Global pharma major Sanofi has entered into a license agreement with Glenmark Pharmaceuticals SA, a wholly owned unit of India’s Glenmark Pharma for development and commercialization of GBR500, a monoclonal antibody to treat Crohn’s disease and other chronic autoimmune disorders.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347